Rethinking capital – Alternative funding models for biotech

Key takeaways

• How alternative financing models are giving biotech companies new ways to fund progress at every stage of development
• The role of structured liquidity in strengthening syndicate alignment, supporting long-term investors and enabling continued scientific execution
• How bespoke funding structures can create stability
• How family offices, angel investors and strategic private investors are bringing longer-term, values-based perspectives into biotech financing
• Practical approaches for leadership teams to evaluate capital options that drive innovation, retain control and accelerate timelines